Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_4
1
50%
Ph phase_1
1
50%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Completed(1)

Detailed Status

Completed1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (50.0%)
Phase 41 (50.0%)

Trials by Status

completed150%
not_yet_recruiting150%

Recent Activity

0 active trials
Showing 2 of 2
not_yet_recruitingphase_4

This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination.

NCT07570888
completedphase_1

A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without Food

NCT06624072

Clinical Trials (2)

Showing 2 of 2 trials
NCT07570888Phase 4

This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination.

Not Yet Recruiting
NCT06624072Phase 1

A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without Food

Completed

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2